Plasma exchange combined with rituximab for the treatment of passenger lymphocyte syndrome after liver transplantation
10.13303/j.cjbt.issn.1004-549x.2025.10.017
- VernacularTitle:一例血浆置换联合利妥昔单抗治疗肝移植术后过客淋巴细胞综合征报告
- Author:
Chenggao WU
1
;
Juan ZOU
2
;
Piaoping HU
2
;
Wei LIU
1
;
Linju KUANG
2
;
Yize WU
2
;
Aiping LE
1
Author Information
1. Transfusion medicine department, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China; Key Laboratory of Jiangxi Province for Transfusion Medicine, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China
2. Transfusion medicine department, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China
- Publication Type:Journal Article
- Keywords:
passenger lymphocyte syndrome;
liver transplantation;
plasma exchange;
rituximab
- From:
Chinese Journal of Blood Transfusion
2025;38(10):1408-1412
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the efficacy of therapeutic plasma exchange and rituximab in the treatment of passenger lymphocyte syndrome (PLS) after ABO incompatible liver transplantation. Methods: PLS diagnosis was performed on the transplant patient using immunohematology testing techniques such as direct anti human globulin test (DAT), red blood cell elution test, and blood type antibody titer detection, combined with changes in hemolysis laboratory indicators; Severe immune hemolysis caused by PLS treated with red blood cell transfusion, therapeutic plasma exchange, and rituximab. Results: The patient was diagnosed with PLS 9 days after transplantation, and hemolysis caused by PLS continued until 20 days after transplantation; After three rounds of therapeutic plasma exchange and treatment with 100 mg rituximab, the titer of the patient's immune blood type antibody (IgG anti-B) decreased from 128 to 8 and was maintained until 27 days after transplantation. The patient's hemolytic symptoms improved and were discharged 32 days after transplantation. Conclusion: This case explores the application of therapeutic plasma exchange and rituximab in the treatment of severe hemolysis in PLS after transplantation, providing a reference for establishing standardized management of PLS after solid organ transplantation.
